The board members will advise UK-based ReNeuron Group plc on the clinical development of the ReN009 therapy and review and monitor its progress along the clinical development pathway. Professor Madeddu is joined on the newly established board by three other eminent heart experts, from Stanford University, California, the University of Colorado Denver, and Northwestern University, Chicago.

Professor Madeddu’s research activities have resulted in over 170 peer-reviewed publications. His research focuses on the development of more effective treatments for disorders caused by insufficient flow of blood to the heart or limbs, and diabetes-related conditions such as impaired wound healing. More recently, his research, in collaboration with ReNeuron, has explored the potential of stem cell transplantation to grow new blood vessels.

ReNeuron’s primary objective is the development of stem cell therapies targeting areas of unmet or poorly met medical need. Dr John Sinden, Chief Scientific Officer of ReNeuron, said: ‘We are delighted to have established a PAD Clinical Advisory Board of such eminent scientists in their field, reflecting the clinical potential of our ReN009 therapy. Their highly accomplished and wide-ranging research and clinical expertise and experience, in both the UK and the US, will prove invaluable as we take our ReN009 therapy for PAD to the clinic.’